The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
about
Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis.Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patientsCardiovascular risk factors and 30-year cardiovascular risk in homeless adults with mental illnessZiprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profilesEffects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders.Pharmacological approaches to the management of schizophrenia: 10 years on.Do antipsychotics increase diabetes risk in children and adolescents?Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics.Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review.Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.Real-world risk of diabetes with antipsychotic use in older New Zealanders: a case-crossover study.Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.Post authorization safety study comparing quetiapine to risperidone and olanzapine.Risk of weight gain for specific antipsychotic drugs: a meta-analysis.
P2860
Q30654033-14654F97-BA0B-487A-A9C4-8E9C15BF1B90Q33915509-F7BC82AE-380B-4FB0-94B0-D56E9B75E438Q34101759-93605D96-BBD0-4894-BC48-BDDBCFD67A8EQ34623350-6665CAC4-4CDD-47C4-B682-68C75FA7BAF8Q34631699-810398E3-FC23-4EA4-825D-E3550B9D238EQ34661651-6935633F-9BE4-4071-BEF8-7CBFA803E3FEQ35118808-FD5B367A-386B-4D09-B372-2BDCDEC8D76DQ35577365-4BD53FDB-7FC4-4758-89A4-F5676AD6748BQ35754726-9A05D970-92A7-4B31-9A82-CBA946B2441BQ35833294-FAC7020F-2304-469D-B3B9-7FF60B4074C4Q36063735-4E0E1127-7C24-425D-8F03-DE8D400E3AF7Q37737291-B83BD515-32C7-4AEE-9B51-EB277EEE9F70Q37914103-84A845A8-512E-4080-ADFD-F6D40243515CQ37947095-EB8EDD96-E01E-4455-9811-8CEA28E94224Q38012489-2BB462B1-0949-4AFE-99BA-9F6D6A7D07F0Q38101540-7CFEB929-5032-4609-9A41-1EA01E406642Q38283956-E804FAF5-D198-4CAF-AB43-23A30AB24F58Q38599502-305E5177-FAEA-46A3-9512-BFBDE1A72FCBQ38826676-130704B5-CA1D-4F67-9240-17C40E39E0A3Q38837641-E97A6295-756A-498E-8934-32EEC415704AQ38859087-1EE2CBB2-BA50-4393-A756-E354B879D71FQ40457990-C08A2272-9338-4EB7-BAB9-210596B945BFQ45226871-4DE0BC43-A02B-4091-995C-FBCC5DDFB49FQ48052280-65F20771-F99C-476C-8B23-15D48B9AB065Q55513508-33E22FB2-C17F-4F79-8E1D-26EA7472A4F0
P2860
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
The incidence of diabetes in a ...... multisite epidemiologic study.
@en
The incidence of diabetes in a ...... multisite epidemiologic study.
@nl
type
label
The incidence of diabetes in a ...... multisite epidemiologic study.
@en
The incidence of diabetes in a ...... multisite epidemiologic study.
@nl
prefLabel
The incidence of diabetes in a ...... multisite epidemiologic study.
@en
The incidence of diabetes in a ...... multisite epidemiologic study.
@nl
P2093
P356
P1476
The incidence of diabetes in a ...... multisite epidemiologic study.
@en
P2093
Ai-Lin Tsai
Charles P Quesenberry
Gerald DeLorenze
Gilbert L'Italien
John Newcomer
Marianne Ulcickas Yood
Robert McQuade
Susan A Oliveria
Vincent J Willey
P304
P356
10.1002/PDS.1781
P577
2009-09-01T00:00:00Z